- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04909866
The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study
May 27, 2021 updated by: Bin Xiong, Wuhan Union Hospital, China
This study is a single-center, single-arm, open-label prospective clinical trial.
By recording the disease-free progression (PFS), overall survival (OS) and tumor treatment response of the included patients, it is planned to evaluate TACE, lenvatinib and carrelizumab in the treatment of BCLC B/C hepatocytes Survival benefits of cancer patients; at the same time, the immune indicators before and after treatment are tested, the dosage is optimized, and the mechanism of combination therapy in liver cancer is explored to lay the foundation for screening more suitable treatment populations; laboratory testing indicators and adverse events To observe and evaluate the safety of combined therapy; adopt immunohistochemistry, pathology, cell biology, proteomics and imagingomics methods to comprehensively evaluate the changes after combined therapy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
At present, the treatment methods for advanced liver cancer mainly include local interventional therapy, targeted therapy and immunotherapy.This study focused on patients with primary HCC diagnosed clinically and radiologically, histologically, or cytologically, in BCLC stage B/C.To study the medium and long-term efficacy of TACE and remvaritinib combined with carrelizumab in the treatment of BCLCB/C stage liver cancer, and to evaluate its effectiveness;To evaluate the safety and efficacy of remvatinib combined with carrelizumab in the treatment of liver cancer, and to clarify the application value of combined therapy, so as to lay a foundation for the evaluation of clinical efficacy in patients with middle and advanced liver cancer.Immune checkpoint inhibitors and cell-based cancer immunotherapies have been widely used in a variety of advanced malignancies by modulating the tumor immune response.Studies have shown that programmed death receptor 1 (PD-1) is an immune checkpoint molecule that negatively regulates the immune function of T cells through interaction with its ligand PD-L1.A growing body of evidence suggests that the PD-1/PD-L1 interaction is one of the major cancer avoidance mechanisms in humans.Overexpression of PD-L1 or PD-L2 by tumor cells interacts with PD-1 molecules expressed in activated T cells to inhibit T cell receptor (TCR) signal transduction, and eventually leads to inactivation of effector T cells and loss of proliferative ability, leading to tumor immune escape.Based on this mechanism of tumors, new immunotherapies that block the interaction between PD1/PD-L1 have been produced, changing the treatment strategies of various malignant tumors.By inhibiting the negative regulatory effect of PD-1/PD-L1 pathway on T cells, the anti-tumor immune response of the body can be enhanced, the T cell response activity targeting the patient's tumor can be improved, and the proliferation of effector T lymphocytes can be promoted, finally providing an important and lasting immune response against the patient's malignant tumor.Carrelizumab is a human high-affinity IgG4 anti-PD-1 monoclonal antibody drug independently developed by Suzhou Henrui Pharmaceutical Co., Ltd., which can selectively block the activation of PD-1 and its downstream signaling pathway, and restore immune function by activating effector T lymphocytes and cell-mediated immune response.Some studies have shown that the application of carrelizumab in patients with advanced solid tumors shows some clinical value, and predictive biomarkers such as PD-L1 expression level and tumor mutation load can screen out patients with high response to PD-1/PD-L1 monoclonal antibodies.Even so, PD1/PD-L1 blocking therapy provides clinical benefit in less than 20% of cancer patients,suggesting that patients using these drugs rely solely on their insufficient preexisting endogenous anti-tumor specific T cells.Anti-angiogenic drugs can specifically bind to vascular endothelial growth factor (VEGF) and its receptor 2(VEGFR2), achieving the dual effect of enhancing cytotoxic chemotherapy and achieving molecular targeted therapy.Some recent studies have shown that angiogenesis inhibitors can regulate tumor microenvironment and relieve hypoxia of tumor cells, which may promote tumor immune recovery .Ramvatinib mesylate is a class of multi-target receptor tyrosine kinase inhibitors, which can block a series of regulatory factors including VEGFR1-3, KIT and RET in tumor cells, and significantly inhibit angiogenesis in tumor tissues.It is currently FDA approved as a first-line treatment for patients with unresectable hepatocellular carcinoma.In a phase III clinical study, the overall survival of remvatinib in the first-line treatment of unresectable hepatocellular carcinoma was comparable to sorafenib (13.6 vs12.3 months) .Another basic study showed that rumvatinib modulates cancer immunity in the tumor microenvironment by reducing tumor-associated macrophages (TAM), and that when combined with PD-1 inhibitors, it can enhance anti-tumor activity through the IFN signaling pathway.In addition, previous studies have found that transarterial chemoembolization (TACE) combined with antiangiogenic agents in the treatment of advanced hepatocellular carcinoma shows a good response to tumor treatment compared with TACE alone, but the incidence of treatment-related adverse events is high and the survival time of patients is not significantly improved.Therefore, in this study, TACE, the powerful anti-angiogenic drug Ramvatinib and the new PD-1 inhibitor Carrizumab were combined to treat liver cancer patients, so as to improve the quality of life of patients and improve their survival benefits.This study aims to explore the clinical outcomes of TACE, Ramvatinib combined with carririzumab in patients with stage BCLCB/C liver cancer, monitor the complications and tumor treatment response of patients, study the appropriate population for combined treatment, and evaluate the hepatorenal and cardiotoxicity of the drugs in humans.Focusing on exploring the mechanism and application value of antiangiogenic therapy combined with immunotherapy in the treatment of liver cancer, to provide new treatment options for patients with middle and advanced liver cancer.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Wuhan Union Hospital
-
Contact:
- Bin Xiong
- Phone Number: 18627081029
- Email: herr_xiong@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- From 18 to 75 years old, there are no gender restrictions, and the pre-survival period exceeds 12 weeks;
- Primary liver cancer diagnosed by clinical and imaging studies, histology or cytology;
- Liver cancer patients with B/C stage according to BCLC staging;
- Have not used molecular targeted therapy drugs or immune checkpoint inhibitors in the past;
- The behavioral status score of the Eastern Cooperative Oncology Group (ECOG) is 0 or 1;
- The main organ functions are normal, and there is no serious blood, heart, lung, liver, kidney dysfunction and immune deficiency diseases. Laboratory examination meets the following requirements: a. Hemoglobin (HGB) ≥ 90g/L; b. Neutrophil count (ANC) ≥ 1.5×109/L; c. Platelet count (PLT) ≥ 100×109/L; d. ALT and AST≤2.5×ULN; liver metastasis, then ALT and AST≤5×ULN; e. total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); f. serum Cr≤1'ULN, Endogenous creatinine clearance rate>50ml/min (Cockcroft-Gault formula); g. Urine routine is normal, or urine protein <(++), or 24-hour urine protein <1.0 g;
- The coagulation function is normal, without active bleeding and thrombosis: a. International standardized ratio INR≤1.5×ULN; b. Partial thromboplastin time APTT≤1.5×ULN; c. Prothrombin time PT≤1.5×ULN ;
- The subject voluntarily joined the study and signed an informed consent form.
Exclusion Criteria:
- Suffer from active malignant tumors other than liver cancer within five years or at the same time. Cured localized tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, etc. can be included in the group;
- Liver cancer tumor size ≥ 70% of liver parenchyma or extrahepatic metastasis;
- Pregnant or lactating women;
- Known allergy to carrelizumab, lenvatinib or pharmaceutical excipients;
- Go through other anti-tumor treatments, including surgical treatment, local treatment and systemic treatment within 4 weeks before enrollment;
- Have received organ or allogeneic bone marrow transplantation;
- Suffer from any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, thyroid ·Reduced function (can be included after hormone replacement therapy)); Immune suppressive drugs have been used within 14 days before the first use of the study drug, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroid hormones (ie not more than 10 mg/day prednisolone or equivalent drug physiology Doses of other corticosteroids);
- Vaccination of live attenuated vaccine within 4 weeks before the first administration or planned during the study period;
- Severe infections (such as intravenous infusion of antibiotics, antifungal or antiviral drugs) within 4 weeks before the first administration, or unexplained fever >38.5°C during the screening period/before the first administration;
- Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- There is objective evidence showing that he has suffered from pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severely impaired lung function, etc.;
- Suffering from hypertension who cannot fall to the normal range after 3 months of treatment with antihypertensive drugs (systolic blood pressure ≤ 140 mmHg / diastolic blood pressure ≤ 90 mmHg);
- Suffer from uncontrollable clinical symptoms or diseases of the heart, including but not limited to congestive heart failure (NYHA grade> Ⅱ grade); unstable or severe angina pectoris; acute myocardial infarction within 6 months; clinically significant Patients with supraventricular or ventricular arrhythmia requiring clinical intervention; left ventricular ejection fraction (LVEF) <50%; Patients with active bleeding due to various reasons or patients at risk of severe bleeding, including but not limited to severe bleeding (bleeding> 30 ml within 3 months), hemoptysis (bleeding> 5 ml within 4 weeks) and occurring within 12 months Thromboembolic events (including stroke events and/or transient ischemic attacks);
- Participated in other clinical trials or participated in any other drug clinical research within 4 weeks, or no more than 5 half-lives from the last study drug;
- Other situations deemed unsuitable by the researcher.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TACE+Lenvatinib+Camrelizumab
|
Patients included in the trial were treated with TACE, lenvatinib combined with Camrelizumab.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: The period of time between the date of randomization until the date of first documented progression , assessed up to 24 months
|
progression free survival
|
The period of time between the date of randomization until the date of first documented progression , assessed up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
OS
Time Frame: From date of randomization until the date of death from any cause, assessed up to 24 months
|
Overall Survival
|
From date of randomization until the date of death from any cause, assessed up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Anticipated)
September 1, 2022
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
February 9, 2021
First Submitted That Met QC Criteria
May 27, 2021
First Posted (Actual)
June 2, 2021
Study Record Updates
Last Update Posted (Actual)
June 2, 2021
Last Update Submitted That Met QC Criteria
May 27, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CXPJJH12000001-2020223
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on TACE+Lenvatininb+Camrelizumab
-
Shanghai Zhongshan HospitalEnrolling by invitationHepatocellular CarcinomaChina
-
Tongji HospitalRecruitingIntrahepatic CholangiocarcinomaChina
-
Zhongda HospitalActive, not recruitingHepatocellular CarcinomaChina
-
Sichuan UniversityNot yet recruitingCarrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular CarcinomaChina
-
Shanghai Zhongshan HospitalNot yet recruitingUnresectable Hepatocellular Carcinoma
-
Shanghai Zhongshan HospitalRecruitingHepatocellular Carcinoma | Immunotherapy | Molecular Targeted TherapyChina
-
Shandong Provincial HospitalUnknown
-
Zhejiang Cancer HospitalUnknown
-
Wen TianfuRecruitingAdvanced Hepatocellular CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHepatocellular CarcinomaChina